Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Belite Bio, Inc BLTE
$26.45
-$0.53 (-2.00%)
На 18:05, 12 мая 2023
Ключевые показатели
-
Marketcap
626658480.00000000
-
week52high
44.70
-
week52low
11.96
-
Revenue
0
-
P/E TTM
0
-
Beta
0.00000000
-
EPS
-0.62000000
-
Last Dividend
0.00000000
-
Next Earnings Date
05 мая 2023 г. в 04:00
Описание компании
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
3 Breakout Growth Stocks to Buy for the Long Haul
The Motley Fool
09 янв 2023 г. в 08:45
These three have had big-time share gains backed up by breakthrough science.
These Are the 10 Best-Performing IPOs in 2022 Through October
24/7 Wall Street
16 ноя 2022 г. в 21:21
The IPO market has been slow this year as investors' risk appetite for new issues hit a record low.
Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers Today
Investors Business Daily
03 окт 2022 г. в 12:22
Apellis and Belite Bio were among the worst-performing biotech stocks Monday after presenting test results in two eye diseases. The post Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers Today appeared first on Investor's Business Daily.
Belite Bio, Inc's (BLTE) CEO Tom Lin on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
13 авг 2022 г. в 02:35
Belite Bio, Inc (NASDAQ:BLTE ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Tom Lin – Chief Executive Officer Nathan Mata – Chief Scientific Officer Hao-Yuan Chuang – Chief Financial Officer Conference Call Participants Bruce Jackson – The Benchmark Company Unidentified Company Representative [Call Starts Abruptly] First Half 2022 Financial Results Conference Call. After today's presentation, there will be an opportunity to ask questions.
Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results
GlobeNewsWire
01 авг 2022 г. в 16:10
SAN DIEGO, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, will host a conference call on Thursday, August 11, 2022, at 4:30 p.m. Eastern time to discuss the Company's financial results for the first half, ended June 30, 2022, and provide a corporate progress update. The financial results will be issued in a press release on Wednesday, August 10, 2022.